C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter L—Regulations Under Certain Other Acts Administered By the Food and Drug AdministrationPart 1271—Human Cells, Tissues, And Cellular and Tissue-Based ProductsSubpart A—General Provisions

21 C.F.R. § 1271.15 (2026)

Are there any exceptions from the requirements of this part?

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 3 IN 5Y cited 2016–2024 5citing cases
At a glance

Courts have cited this section in 5 opinions since 2016, 3 of them in the last five years. The most litigated part is subsection (b) (4 cases).

(a) You are not required to comply with the requirements of this part if you are an establishment that uses HCT/P's solely for nonclinical scientific or educational purposes.

(b) You are not required to comply with the requirements of this part if you are an establishment that removes HCT/P's from an individual and implants such HCT/P's into the same individual during the same surgical procedure.

(c) You are not required to comply with the requirements of this part if you are a carrier who accepts, receives, carries, or delivers HCT/P's in the usual course of business as a carrier.

(d) You are not required to comply with the requirements of this part if you are an establishment that does not recover, screen, test, process, label, package, or distribute, but only receives or stores HCT/P's solely for implantation, transplantation, infusion, or transfer within your facility.

(e) You are not required to comply with the requirements of this part if you are an establishment that only recovers reproductive cells or tissue and immediately transfers them into a sexually intimate partner of the cell or tissue donor.

(f) You are not required to register or list your HCT/P's independently, but you must comply with all other applicable requirements in this part, if you are an individual under contract, agreement, or other arrangement with a registered establishment and engaged solely in recovering cells or tissues and sending the recovered cells or tissues to the registered establishment.

The 5 cases that cite 21 C.F.R. § 1271.15 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
cites § 1271.15 6×subsections: (b)cited by 3 cases
Where it cites § 1271.15
“” 21 C.F.R. § 1271.15 (b). Because the text of the HCT/P regulations does not provide a clear answer to the meaning of the SSP exception, the panel examined the SSP exception’s context and structure and resolved the seeming textual ambiguity in the FDA’s favor.”
2
GREENUnited States v. US Stem Cell Clinic, LLC, 998 F.3d 1302 (11th Cir. 2021).
cites § 1271.15 4×subsections: (b)cited by 4 cases
Where it cites § 1271.15
“See 21 C.F.R. § 1271.15 (b); id. § 1271.10. We disagree: The procedure does not fall within the first exception because the biological material implanted into the patient is not the same as that removed and the procedure does not fall within the second exception * Honorable…”
3
NO FLAGUnited States v. California Stem Cell Treatment Ctr., Inc., 624 F. Supp. 3d 1177 (C.D. Cal. 2022).
cites § 1271.15 2×cited by 0 casesunknown
Where it cites § 1271.15
“” 21 C.F.R. § 1271.15 . 8 7. “HCT/Ps” is an acronym for “[h]uman cells, tissues, or cellular or tissue- 9 based products,” and HCT/Ps are defined in Section 1271.”
4
NO FLAGEnholm v. Cohen, No. D067252 (Cal. Ct. App. Jan. 12, 2016).
cites § 1271.15 1×subsections: (b)cited by 0 casesunpublished
Where it cites § 1271.15
“It is an FDA "Draft Guidance for the Industry" (italics added) relating to the "same surgical procedure exception under 21 CFR 1271.15(b)." Enholm contends this is a "clarification" establishing the CEFT procedure Cohen performed is regulated by the FDA and is unlawful.”
5
NO FLAGEnholm v. Cohen, No. D067252M (Cal. Ct. App. Jan. 29, 2016).
cites § 1271.15 1×subsections: (b)cited by 0 casesunpublished
Where it cites § 1271.15
“It is an FDA "Draft Guidance for the Industry" (italics added) relating to the "same surgical procedure exception under 21 CFR 1271.15(b)." Enholm contends this is a "clarification" establishing the CEFT procedure Cohen performed is regulated by the FDA and is unlawful.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
201620202024

One bar per year. Tallest: 2 cases in 2016. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
Cal. Ct. App.211th Cir.19th Cir.1C.D. Cal.1
By subsection
(b)4 cases
United States v. US Stem Cell Clinic, LLC, 998 F.3d 1302 (11th Cir. 2021).“See 21 C.F.R. § 1271.15 (b); id. § 1271.10. We disagree: The procedure does not fall within the first exception because the biological material implanted into the patient is not the same as that removed and the procedure does not fall within the second exception * Honorable…”
United States v. California Stem Cell Treatment Ctr., Inc., 117 F.4th 1213 (9th Cir. 2024).“” 21 C.F.R. § 1271.15 (b). Because the text of the HCT/P regulations does not provide a clear answer to the meaning of the SSP exception, the panel examined the SSP exception’s context and structure and resolved the seeming textual ambiguity in the FDA’s favor.”
Enholm v. Cohen, No. D067252 (Cal. Ct. App. Jan. 12, 2016).“It is an FDA "Draft Guidance for the Industry" (italics added) relating to the "same surgical procedure exception under 21 CFR 1271.15(b)." Enholm contends this is a "clarification" establishing the CEFT procedure Cohen performed is regulated by the FDA and is unlawful.”
Enholm v. Cohen, No. D067252M (Cal. Ct. App. Jan. 29, 2016).“It is an FDA "Draft Guidance for the Industry" (italics added) relating to the "same surgical procedure exception under 21 CFR 1271.15(b)." Enholm contends this is a "clarification" establishing the CEFT procedure Cohen performed is regulated by the FDA and is unlawful.”
Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com